209 related articles for article (PubMed ID: 8589229)
1. Incorporating toxicity considerations into the design of two-stage phase II clinical trials.
Bryant J; Day R
Biometrics; 1995 Dec; 51(4):1372-83. PubMed ID: 8589229
[TBL] [Abstract][Full Text] [Related]
2. Curtailed two-stage designs in Phase II clinical trials.
Chi Y; Chen CM
Stat Med; 2008 Dec; 27(29):6175-89. PubMed ID: 18816510
[TBL] [Abstract][Full Text] [Related]
3. Designs for phase II trials allowing for a trade-off between response and toxicity.
Conaway MR; Petroni GR
Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
[TBL] [Abstract][Full Text] [Related]
4. Methods of joint evaluation of efficacy and toxicity in phase II clinical trials.
Tournoux C; De Rycke Y; Médioni J; Asselain B
Contemp Clin Trials; 2007 Jul; 28(4):514-24. PubMed ID: 17331808
[TBL] [Abstract][Full Text] [Related]
5. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
6. Sample size determination for phase II clinical trials based on Bayesian decision theory.
Stallard N
Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
[TBL] [Abstract][Full Text] [Related]
7. Adaptive two-stage designs in phase II clinical trials.
Banerjee A; Tsiatis AA
Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
[TBL] [Abstract][Full Text] [Related]
8. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
9. Curtailed two-stage designs with two dependent binary endpoints.
Chen CM; Chi Y
Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348
[TBL] [Abstract][Full Text] [Related]
10. Alternative designs of phase II trials considering response and toxicity.
Jin H
Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
[TBL] [Abstract][Full Text] [Related]
11. Stochastically curtailed phase II clinical trials.
Ayanlowo AO; Redden DT
Stat Med; 2007 Mar; 26(7):1462-72. PubMed ID: 16900560
[TBL] [Abstract][Full Text] [Related]
12. Admissible two-stage designs for phase II cancer clinical trials.
Jung SH; Lee T; Kim K; George SL
Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
[TBL] [Abstract][Full Text] [Related]
13. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
Yin G; Li Y; Ji Y
Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
[TBL] [Abstract][Full Text] [Related]
14. A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials.
Jin H; Wei Z
Contemp Clin Trials; 2012 Nov; 33(6):1255-60. PubMed ID: 22772088
[TBL] [Abstract][Full Text] [Related]
15. Balanced two-stage designs for phase II clinical trials.
Ye F; Shyr Y
Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trials with a prospective control.
Jung SH
Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
[TBL] [Abstract][Full Text] [Related]
17. On Simon's two-stage design for single-arm phase IIA cancer clinical trials under beta-binomial distribution.
Liu J; Lin Y; Shih WJ
Stat Med; 2010 May; 29(10):1084-95. PubMed ID: 20077506
[TBL] [Abstract][Full Text] [Related]
18. Interval estimation of binomial proportion in clinical trials with a two-stage design.
Tsai WY; Chi Y; Chen CM
Stat Med; 2008 Jan; 27(1):15-35. PubMed ID: 17566141
[TBL] [Abstract][Full Text] [Related]
19. Two-stage k-sample designs for the ordered alternative problem.
Shan G; Hutson AD; Wilding GE
Pharm Stat; 2012; 11(4):287-94. PubMed ID: 22408050
[TBL] [Abstract][Full Text] [Related]
20. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
Masaki N; Koyama T; Yoshimura I; Hamada C
J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
